Abstract: The use of certain 6-arylpyrazolo[3,4-d]pyrimidin-4-ones, 2 arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido[3,2-d]pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said animal with said pharmaceutical composition or with said either entity.

Abstract: The invention relates to the novel use of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide, a pharmacologically tolerable salt thereof or its N-oxide in the treatment of multiple sclerosis.

Abstract: The present invention provides methods and pharmaceutical compositions for treating or inhibiting urinary stone disease that involve administering to an individual with urinary stone disease or at risk of developing urinary stone disease an amount effective of pyridoxamine to reduce urinary oxalate concentrations.

Abstract: This application relates to a pharmaceutical composition for the prevention, treatment, and management of scalp conditions, such as dandruff, seborrheic dermatitis, psoriasis, folliculitis, and hair thinning including a therapeutically effective amount of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable salt thereof. A preferred anti-dandruff composition and method of managing dandruff includes a therapeutically effective amount of the acid component, a vitamin A component, and an anti-growth agent. A preferred anti-hair thinning composition and method of managing thinning hair includes a therapeutically effective amount of the acidic component, a niacin component present in an amount sufficient to locally increase blood circulation, and a 5-&agr; reductase inhibitor.

Abstract: A liquid aqueous pharmaceutical suspension formulation containing as amoxycillin trihydrate, potassium clavulanate and microcrystalline cellulose filler is provided.

Abstract: A method of treating protozoan infections in fish comprising introducing a sufficient quantity of one or more photoactive dyes to an aqueous environment containing one or more fish infected with protozoa such that the resulting concentration of the one or more photoactive dyes in the aqueous environment is toxic to at least some of the protozoa.

Abstract: An antimicrobial composition comprising (i) between 0.025 and 2 percent of an antimicrobial agent selected from the group consisting of chlorhexidine free base, a chlorhexidine salt, polyhexamethylene biguanide, and alexidine; (ii) between 0.005 and 0.1 percent of a quaternary ammonium compound; and (iii) between 0.025 and 2 percent of a chlorinated phenol compound.

Abstract: The present invention offers a tracheal smooth muscle relaxant containing the compound represented by the following formula (1) or pharmacologically acceptable salt thereof as an effective ingredient.

Abstract: A cyclooxygenase-2-inhibitor containing as an active ingredient a compound having cyclooxygenase-2-inhibitory activity and exhibiting low toxicity that causes only minor side effects. The active compound is represented by the following formula (1) or (1′): wherein R1 represents a hydrogen atom or a C1-C3 alkyl group; R2 represents a hydrogen atom, a hydroxyl group, an organic group capable of being bound through its thiol group within the molecule, or R1 and R2 may join to each other to form a single bond; R3 represents a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 alkoxyl group, a trifluoromethyl group, or a nitro group; each of R4 and R5, which may be identical to or different from each other, represents a hydrogen atom, a halogen atom, a C1-C4 alkoxyl group, a trifluoromethyl group, or R4 and R5 may join to each other to form a methylenedioxy group.

Abstract: A method for preventing or treating drug dependence comprising administering to a human in need thereof a pharmaceutically effective amount of a 1,4-(diphenylalkyl)piperazine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkoxy; R2 is lower alkoxy; A is lower alkylene and B is lower alkylene;

Abstract: The subject invention provides a method of treating mania in bipolar disorder in a subject comprising administering to the subject a therapeutically effective amount of derivatives of 1-aminoindan or their racemic mixtures, enantiomers, or salts, of the general formula: wherein n is 0 or 1; each of R1 and R2 are hydrogen, C1-C4 alkyl, halogen; R3 is hydrogen, C1-C4 alkyl, hydroxy, C1-C4 alkoxy; R4 is hydrogen, C1-C4 alkyl; R6 is hydrogen, substituted or unsubstituted C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl or A—N—R9R10, provided that R6 is not methyl when R1, R2, R3 and R4 are hydrogen atoms, wherein A is substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C7-C12 aralkyl, and each of R9 and R10 are independently hydrogen, C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl, COOtBu, or indanyl; and racemic mixtures, enantiomers, and salts thereof.

Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.

Abstract: The present invention relates to compositions containg i) from about 0.0001% to about 99.9% of certain compounds selected from the group consisting of lupane triterpenes, derivatives of lupane triterpenes, derivatives of oleanane triterpenes, derivatives of ursane triterpenes, and salts and mixtures thereof, and ii) a vehicle.

Abstract: The invention describes novel methods for treating and preventing cognitive impairments caused by traumatic brain injuries by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT®.

Abstract: The present invention provides novel soy formulations comprising 3-23 milligrams of at least one isoflavone per gram of the formulation. The soy formulations may additionally comprise 0.4 to 1.2 grams of protein per gram of the formulation. In another aspect, the present invention provides novel soy formulations comprising diadzin, genistin and glycitin in a ratio of 3:1:2 to 3:4.5:1, preferably approximately 2:1:1 such that diadzin is a major isoflavone component. The present invention further provides dietary supplements and food products comprising a soy formulation of the present invention. In another aspect the present invention provides pharmacological compositions comprising a soy formulation of the present invention. The pharmacological compositions may additionally comprise a medicinal composition.

Abstract: The likelihood of chlamydia infection can be prevented by the topical application of metallo-organic cobalt compounds according to the following formula to the cite of infection: wherein each A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group; each Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure wherein R is hydrogen, an alkoxide group, and alkyl group, or OH; each B may be the same or different and each is hydrogen or an alkyl group; each X may be the same or different and each is a water soluble group having weak to intermediate ligand filed strength; and Z− is a soluble, pharmaceutically acceptable negative ion. Metallo-organic cobalt compounds may also be used to disinfect liquids which contain chlamydia.

Abstract: The invention pertains to methods for introducing an estrogenic compound into a subject in need thereof involving administering an effective amount of a ring system compound having the formula (II) wherein each of R1 and R2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl, and at least one of R1 and R2 is H, or together represent alkylene optionally containing one or more hetero atoms or groups in the alkylene chain; and the ring system ABCD represents a substituted or unsubstituted, saturated or unsaturated steroid nucleus selected from the group consisting of oestrones, dehydroepiandrosterones, substituted oestrones, oestradiols, substituted oestradiols, oestriols, substituted dehydroepiandrosterones, or substituted oestriols; wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3,1,6,2), or a pharmceutically acceptable salt thereof.

Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula:  wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a &bgr;-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.

Abstract: Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-propanedinitrile, which has been previously suggested for tho treatment of congestive heart failure is useful in the treatment of pulmonary hypertension.

Abstract: This invention relates to a method for the treatment and prevention of migraine and affective illness by administering a therapeutically effective amount of the valproic acid analog 2-n-propyl-4-hexynoic acid. The compound 2-n-propyl-4-hexynoic acid is an effective anti-migraine and anti-affective illness drug with greatly reduced adverse effects including neurotoxicity and teratogenic potential compared to valproic acid. This invention thus provides an improved method for treating and preventing migraine and affective illness.